8-K: Ionis Pharmaceuticals Announces Positive Topline Results from Essence Study of Olezarsen for Moderate Hypertriglyceridemia

Ionis Pharmaceuticals reports positive topline results from the Essence study, showing that olezarsen significantly reduced triglycerides in people with moderate hypertriglyceridemia.

Summary

• Ionis Pharmaceuticals announced positive topline results from the Essence study of olezarsen.
• The study involved people with moderate hypertriglyceridemia (fasting triglycerides 150 mg/dL to <500 mg/dL) with or at risk for atherosclerotic cardiovascular disease (ASCVD).
• Olezarsen met the primary endpoint, demonstrating a statistically significant mean reduction in triglycerides versus placebo at 80 mg and 50 mg doses.
• The placebo-adjusted reduction in triglyceride levels at 6 months was 61% and 58% with the 80 mg and 50 mg monthly doses, respectively (p <0.0001).
• Olezarsen also met all key secondary endpoints in the study.
• The vast majority of participants reached <150mg/dL, reflecting a reduction to normal TG levels.
• Olezarsen demonstrated a favorable safety and tolerability profile.
• Data from the pivotal Phase 3 CORE and CORE2 studies of olezarsen in severe hypertriglyceridemia (sHTG) are expected in Q3 2025.
• Ionis plans to submit an abstract for presentation at an upcoming scientific conference.
• The Essence study enrolled 1,478 participants aged 18 and older.
• Participants received either 50 mg (n=276) or 80 mg (n=832) of olezarsen or placebo (n=369) every 4 weeks via subcutaneous injection for 12 months.

Sentiment

Score: 8

Explanation: The document presents positive topline results from a Phase 3 study, indicating potential for a new treatment option. The favorable safety profile and achievement of key endpoints contribute to a positive outlook.

Positives

• Olezarsen demonstrated a statistically significant reduction in triglycerides compared to placebo.
• The drug met all key secondary endpoints in the Essence study.
• Olezarsen showed a favorable safety and tolerability profile.
• The study supports the exposure database for olezarsen with nearly 1,500 participants.
• The vast majority of participants reached normal TG levels of <150mg/dL.

Negatives

• The most common treatment-emergent adverse event was injection site reactions, though the majority were mild in severity.

Risks

• The success of olezarsen is contingent on the results of the Phase 3 CORE and CORE2 studies.
• The drug has not yet been approved for the treatment of sHTG by regulatory authorities.
• Hypersensitivity reactions have been reported in patients treated with TRYNGOLZA, requiring medical treatment.

Future Outlook

Ionis anticipates the results of the Phase 3 CORE and CORE2 studies in Q3 2025, which will form the basis for a potential sNDA filing for olezarsen in sHTG by year-end.

Management Comments

• Sam Tsimikas, M.D., senior vice president, global cardiovascular development at Ionis, stated that the positive results are an important step in bringing forward a potential new treatment for people with severely elevated triglycerides.
• He also mentioned that the data support olezarsen's potential to benefit the broader population of people living with sHTG.

Industry Context

The announcement positions Ionis Pharmaceuticals to potentially address a significant market with olezarsen, targeting both moderate and severe hypertriglyceridemia, a condition affecting millions and putting them at risk of acute pancreatitis and atherosclerotic cardiovascular disease.

Comparison to Industry Standards

• Current treatments for hypertriglyceridemia often involve lifestyle changes and medications like fibrates and omega-3 fatty acids.
• The 61% and 58% reduction in triglyceride levels demonstrated by olezarsen in the Essence study appears competitive compared to some existing therapies, but a full comparison requires a review of the complete data set and head-to-head trials.
• Companies like Amarin with Vascepa (icosapent ethyl) and other pharmaceutical companies developing novel lipid-lowering therapies are direct competitors in this space.
• The approval of TRYNGOLZA for FCS provides a foundation and market experience for Ionis as they pursue the broader sHTG indication.

Stakeholder Impact

• Shareholders may react positively to the promising clinical trial results.
• Patients with moderate hypertriglyceridemia could benefit from a new treatment option.
• The medical community gains a potential new tool for managing hypertriglyceridemia.

Next Steps

• Ionis plans to submit an abstract for presentation at an upcoming scientific conference.
• The company awaits data from the pivotal Phase 3 CORE and CORE2 studies in Q3 2025.
• Ionis intends to file a potential sNDA for olezarsen in sHTG by year-end.

Key Dates

Keywords

Olezarsen, Hypertriglyceridemia, Ionis Pharmaceuticals, Essence Study, Triglycerides, ASCVD, sHTG, CORE study, CORE2 study, TRYNGOLZA